- Home
- CBRE vs ARGX Comparison
CBRE vs ARGX Comparison
Compare CBRE & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- ARGX
- Stock Information
- Founded
- CBRE 1906
- ARGX 2008
- Country
- CBRE United States
- ARGX Netherlands
- Employees
- CBRE N/A
- ARGX N/A
- Industry
- CBRE Real Estate
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBRE Finance
- ARGX Health Care
- Exchange
- CBRE Nasdaq
- ARGX Nasdaq
- Market Cap
- CBRE 36.2B
- ARGX 40.4B
- IPO Year
- CBRE 2004
- ARGX 2017
- Fundamental
- Price
- CBRE $126.32
- ARGX $573.84
- Analyst Decision
- CBRE Buy
- ARGX Strong Buy
- Analyst Count
- CBRE 9
- ARGX 20
- Target Price
- CBRE $149.22
- ARGX $699.56
- AVG Volume (30 Days)
- CBRE 1.8M
- ARGX 395.2K
- Earning Date
- CBRE 04-24-2025
- ARGX 05-08-2025
- Dividend Yield
- CBRE N/A
- ARGX N/A
- EPS Growth
- CBRE 2.39
- ARGX N/A
- EPS
- CBRE 3.28
- ARGX 15.94
- Revenue
- CBRE $36,742,000,000.00
- ARGX $2,643,062,000.00
- Revenue This Year
- CBRE $13.34
- ARGX $60.97
- Revenue Next Year
- CBRE $9.46
- ARGX $31.50
- P/E Ratio
- CBRE $38.33
- ARGX $35.56
- Revenue Growth
- CBRE 13.15
- ARGX 82.13
- 52 Week Low
- CBRE $84.24
- ARGX $352.77
- 52 Week High
- CBRE $147.75
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- CBRE 55.50
- ARGX 41.23
- Support Level
- CBRE $123.35
- ARGX $529.11
- Resistance Level
- CBRE $127.35
- ARGX $658.93
- Average True Range (ATR)
- CBRE 3.09
- ARGX 15.71
- MACD
- CBRE 1.01
- ARGX -4.50
- Stochastic Oscillator
- CBRE 90.49
- ARGX 34.46
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.